116results about How to "Immunogenic" patented technology

The invention discloses a mixture of poly-pneumococcal capsular polysaccharide-protein conjugates. The mixture contains 13 pneumococcal capsular polysaccharide-protein conjugates and an immunity-enhancement adjuvant, wherein each pneumococcal capsular polysaccharide-protein conjugate is formed by combining corresponding serum-type pneumococcal capsular polysaccharide with a same protein carrier through a covalent bond; the 13 pneumococcal capsular polysaccharides are obtained by purifying and extracting 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F bacteria; the protein carrier is A chain of a diphtherin mutant CRM197 obtained from expression of genetic recombinant escherichia coli. Meanwhile, the invention discloses a preparation method of the mixture. The mixture, compared to conventional bacterial fermentation total-chain diphtherin mutant CRM197, is easy to purify, high in yield and low in cost; experiments prove that the mixture disclosed by the invention is immunogenic, and is applicable to clinical inoculation.

The present invention is diphtheria toxin mutant CRM197 and its preparation process, and belongs to the field of immune protein carrier technology. The diphtheria toxin mutant CRM197 is expressed in colibacillus in the form of inclusion body, and the target product has sequence length of 536 amino acids, the immunogenicity the same as that of diphtheria toxin and no toxicity similar to that of diphtheria toxin. The present invention clones gene coding CRM197, constructs recombinant expression plasmid expressing CRM197 and transforms to colibacillus host for expression in the form of inclusion body. The present invention has target protein accounting for over 24 % of total protein content, high CRM197 purity over 95 % and high target protein recovering rate. The preparation process is simple, low in cost and suitable for industrial production.

The invention discloses a novel chicken infectious bursal disease virusVP 2c DNA (SEQ ID NO: 1), construction of its expression carrier, expressed recombined VP2 protein and the application of said recombined protein in preparing subunit genetic engineering vaccine against chicken infection bursal disease virus. The chicken infectious bursal disease virusVP 2c DNA can be highly expressed in yeast cell, and expressed recombined protein possesses biological activity and immunogenicity of the chicken infectious bursal disease virus natural protein . The expressed recombined protein can be produced into vaccine, and it is demonstrated through immunity chicken test that: the protein subunit vaccine can effectively induce body to generate spcial humoral immune response, make immunity chicken get 90% protection from deadly attack of highly pathogenic vv IBDV, and effectively prevent virus proliferation in the body.

The invention discloses a multi-epitope peptide-loaded DC (dendritic cell) therapeutic vaccine for HCV (hepatitis C viruses), relating to the technical field of virology and immunology. The multi-epitope peptide-loaded DC (dendritic cell) therapeutic vaccine is characterized in that two CTL epitopes (namely, a NS4B (1793-1801) SMMAFSAAL and a P7 (774-782) AAWYIKGRL) are used for constructing recombinant adenoviruses, then the recombinant adenoviruses are used for infecting human dendritic cells so as to prepare a multi-epitope DC vaccine. Detection results indicate that the multi-epitope peptide-loaded DC (dendritic cell) therapeutic vaccine for HCV (hepatitis C viruses) disclosed by the invention has an immunogenicity.

The invention discloses a Japanese encephalitis vaccine prepared by human embryonic lung fibroblasts and a preparation method thereof, comprising culture and expansion of the human embryonic lung fibroblasts. The method comprises the following steps: Japanese encephalitis virus strain P3, strain SA14-14-2 or strain Nakayama is naturalized and inoculated to fit the human embryonic lung fibroblasts, and the seeds of Japanese encephalitis viruses are prepared on the human embryonic lung fibroblasts; wherein, an inactivated Japanese encephalitis vaccine also comprises the steps of harvesting viruses, inactivating viruses, concentrating, purifying and the like; an attenuated live vaccine also comprises the steps of harvesting viruses, concentrating, purifying and the like. Due to being prepared by healthy human embryonic lung fibroblasts, the two kinds of Japanese encephalitis vaccines do not contain any adventitious pollution agent and tumorigenicity, has high purity after being purified and has the advantages of good immune effect and high security. The preparation method of the invention is suitable for large-scale industrial production and can meet the preparation processes of Japanese encephalitis vaccines required by domestic and abroad markets.

The invention provides a construction method for delaying attenuation and increasing an expression exogenous antigen salmonella suipestifer carrier through regulation and control of gene, which is characterized in that receptor bacterium C78-3 is combined with manA, crp, relA and asd -containing deleted suicide carrier escherichia coli donor bacterium, mutants delta manA, delta Pcrp: : TT ara C PBAD crp, delta relA: : araC PBAD lacI TT and delta asd A are introduced in wild-type salmonella suipestifer C78-3, the introduced salmonella suipestifer after mutation can be called x0011; and four types of mutation enable phenotype identification. The method of the invention makes salmonella suipestifer to become safe and effective vaccine carrier of many exogenous antigens; and provides the delaying attenuation and increasing expression exogenous antigen salmonella suipestifer carrier through regulation and control of gene for various pig diseases, especially many bacteria diseases of pig, and has great market applicability.

The invention belongs to the technical field of medicines, and relates to drug-loaded nanoparticles, in particular to adriamycin nanoparticles entrapped by bacterial outer membrane vesicles and an application of the adriamycin nanoparticles. The invention provides adriamycin nanoparticles DOX-OMV which are entrapped by bacterial outer membrane vesicles and are prepared by adopting attenuated klebsiella pneumoniae sourced bacterial OMVs (outer membrane vesicles) to entrap a tumor chemotherapeutic drug DOX (doxorubicin). The test research on the effect of resisting non-small cell lung cancer shows that the DOX-OMV nanoparticles can play a lung cancer cell targeting role and an anti-tumor immune induction effect at the same time, and the half-life period of the drug is prolonged, so that the non-small cell lung cancer resisting curative effect of the chemotherapeutic drug adriamycin is remarkably enhanced, and the DOX-OMV nanoparticles have good safety. The prepared DOX-OMV nanoparticles can be used for preparing drugs for resisting non-small cell lung cancer.

The present invention discloses one coding gene of rotavirus VP6 protein and its application, and aims at providing one coding gene of rotavirus VP6 protein with high expression amount in dicotyledonous plant, especially clover, method of producing oral rotavirus vaccine with the coding gene and the obtained oral vaccine. The rotavirus VP6 protein coding gene has one of the following nucleotide sequences: 1. DNA sequence of SEQ ID No. 1 in the sequence list; 2. DNA sequence of SEQ ID No. 2 in the sequence list; 3. the nucleotide sequence capable of hybridizing in high strict condition with the DNA sequence limited by SEQ ID No. 1 or SEQ ID No. 2; and 4. DNA sequence possessing over 80 % homology with the SEQ ID No. 1 or SEQ ID No. 2 limited DNA sequence and high expression amount in dicotyledonous plant. The oral rotavirus vaccine is used in preventing various rotavirus infection caused acute diarrhea of infant and young animal.

The invention discloses a recombined subunit vaccine of haemaphysalis concinna and a preparation method thereof. The recombined subunit vaccine is formed by mixing antigenic gene recombined protein of the haemaphysalis concinna and Freund's complete adjuvant (FCA), wherein the content of the antigenic gene recombined protein is 50 mg/ml, that is 50 mL rHc-23 and 950 ml Freund's complete adjuvant are mixed to prepare the recombined subunit vaccine of the haemaphysalis concinna; the amino acid sequence of the antigenic gene recombined protein is shown in the table SEQID NO:1; and the nucleotide sequence of the antigenic gene is shown in the table SEQID NO:2. Through screening and cloning, prokaryotic expression and separation and purification of protective antigen gene of the haemaphysalis concinna and the application effect test of the recombined subunit vaccine, the method shows that an expression product of recombined vector bacteria can be identified by rabbit anti-haemaphysalis concinna positive serum. In an animal immunity test, after rHc-23-FCA is subjected to three immune rabbits, the blood saturation rates of haemaphysalis larva, haemaphysalis middle and haemaphysalis imago are 40.3 percent, 45.6 percent and 41.3 percent respectively; and compared with the blood saturation rates of the haemaphysalis larva, haemaphysalis middle and haemaphysalis imago in a contrast set: 90.1 percent, 94.3 percent and 97.7 percent, the differences are remarkable. The method promotes the development of anti-haemaphysalis immunity, haemaphysalis control and haemaphysalis disease spread work.

The invention relates to a mask process of daily necessities, in particular to an application of residual primary culture fluids of mammalian cells in the preparation of active matters of a mask. According to the invention, the residual cell culture fluids are sources of growth factor type matters at home and abroad, and are inexpensive and high in quality, renewable, safe and reliable; silk fibroins can be effectively degraded at the normal temperature by enzymes contained in the residual cell culture fluids, so that small molecular silk fibroins are obtained, and the operation is simple and safe; then sericin in the silk fibroins has immunogenicity so that anaphylaxis may be caused, and the posterior silk gland-derived silk fibroins are completely free of sericin so that the possibility of anaphylaxis is greatly reduced; and the film-forming property of a silk mask is the difficulty of the preparation, a silk I conformation of protein molecules is gradually transformed to silk II in the process of repeatedly stirring and drying the silk fibroins at a high temperature, so that the silk fibroins are stable in structure and have excellent mechanical properties.

The invention discloses mycoplasma bovis enolase and new applications of a coding gene thereof. Specifically, the invention discloses the mycoplasma bovis enolase and applications of the coding gene of the mycoplasma bovis enolase in preparing reagents for detecting plasminogen and detecting or diagnosing infections caused by mycoplasma bovis. According to the mycoplasma bovis enolase disclosed by the invention, an enolase protein is obtained through prokaryotic expression, and soluble expression is successfully performed on the protein through regulating induction conditions, and further, through recombinant enolase protein and plasminogen ligand experiments and enolase protein and mycoplasma bovis antibody Western blot experiments, the protein is finally proved to have the binding activity and the immunogenicity of the plasminogen, therefore, the protein can be used for detecting the plasminogen and detecting or diagnosing the infections or diseases caused by the mycoplasma bovis. Moreover, a new path is also opened up for researching the adhesion mechanism and the pathogenicity of the mycoplasma bovis and developing vaccines in future.

The invention belongs to the technical field of medicines and relates to a nano particle, in particular to a phase change type nano particle. The phase change type nanoparticle is formed by liposome-encapsulated gold nanorods and liquid fluorocarbon, wherein monoclonal antibodies of melanoma-associated antigens are attached to the surfaces of liposomes. The phase change type nanoparticle has phototransformation properties, thereby having superior development and tumor treatment effects; drug encapsulation of the phase change type nano particle is achieved by using a liposome material, so thatthe immunity of the nanoparticle is reduced, and he biocompatibility of the nanoparticle is improved. The nanoparticle prepared by the technical scheme can be applied to contrast agents and therapeutic drugs of melanoma.

The invention relates to a novel antigen epitope peptide based on CD271 and application of the novel antigen epitope peptide. The antigen epitope peptide is: (1) located in SEQ ID NO.1; or (2) is located in an amino acid sequence having at least 80% identity with the SEQ ID NO.1 sequence in (1); wherein SEQ ID NO.1 contains one or more antigen epitopes, and the length of the amino acid sequence of the antigen epitope peptide is 5-70% of the full length of the SEQ ID NO.1. An antibody, a nucleic acid aptamer, a vaccine, nanoparticles and the like targeting the antigen peptide can be stably combined with natural cells with CD271 protein. The antigen epitope peptide or nucleic acid, fusion protein, carrier or host cell and the like containing the antigen epitope peptide have important application significance in the fields of preparation of CD271 related detection reagents, disease treatment biological drugs, vaccines and the like.

The invention provides a method for preparing cyclosporin A (CsA) holoantigen. According to the method, a high pressure mercury lamp is taken as a UV light source of a photochemical reaction, tert-butyl alcohol is taken as a reaction solvent, an intermediate CsA incomplete antigen is obtained by performing an addition reaction on 4-benzoylbenzoic acid and CsA under conditions of the photochemical reaction; the CsA incomplete antigen is dissolved in dimethyl formamide, and reacted with poly-L-lysine in water under the effect of 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride for synthesis of cyclosporin A holoantigen. The method is simple and feasibile and easy to operate, helps to shorten the photochemical reaction time of producing CsA incomplete antigen and substantially save the synthetic process of cyclosporin A holoantigen. ELISA reaction experiments and animal (mice) immunization experiments verify that the CsA holoantigen synthesized by the method has good specificity and immunogenicity, and the method is applicable to synthesis of CsA holoantigen.

The invention provides a bone-grafting filling material and a preparation method thereof. The method comprises the following steps: mixing and crushing biphasic calcium phosphates, calcium sulphate and iron oxide into grains of 0.1-1mm, burning at 800 DEG C for 3 hours, taking out to soak in 1M of (NH4)2HPO4 solution for 24 hours; drying two days, and burning at the temperature of 1100 DEG C for 1-2 days; slowly cooling, rinsing and baking, so as to obtain a skeleton structure; spraying a slow release formulation on a layer of collagen surface; spraying a layer of collagen on the surface of the slow release formulation to obtain a compound protein layer; baking the composite protein layer at 30 DEG C, carrying out superfine grinding, so as to obtain protein particles which are 50-100nm in particle size; finally, adding the skeleton structure and the protein particles to absolute ethyl alcohol; placing under the conditions at 1-5 DEG C and -0.01 to -0.05MPa for 2-3 days, so as to obtain the bone-grafting filling material. The bone-grafting filling material disclosed by the invention has biodegradability and biocompatibility, is free of or low in immunogenicity, strong in bone conductibility, bone inductivity, mechanical tolerance and the like, and kinds of performance requirements required by the bone filling material are completely met.